Log in to save to my catalogue

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Tre...

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Tre...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ad0d07b841e64c82afc2fcdee19751cf

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Selinexor is an oral, selective nuclear export inhibitor. STORM was a phase 2b, single-arm, open-label, multicenter trial of selinexor with low dose dexamethasone in patients with penta-exposed relapsed/refractory multiple myeloma (RRMM) that met its primary endpoint, with overall response of 26% (95% confidence interval [CI], 19 to 35%). Health-re...

Alternative Titles

Full title

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_ad0d07b841e64c82afc2fcdee19751cf

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ad0d07b841e64c82afc2fcdee19751cf

Other Identifiers

ISSN

1471-2407

E-ISSN

1471-2407

DOI

10.1186/s12885-021-08453-9

How to access this item